Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

P. Sonneveld; H. Goldschmidt; L. Rosinol; J. Blade; J.J. Lahuerta; M. Cavo; P. Tacchetti; E. Zamagni; M. Attal; H.M. Lokhorst; A. Desai; A. Cakana; K. Liu; H. van de Velde; D-L. Esseltine; P. Moreau

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

P. Sonneveld, H. Goldschmidt, L. Rosinol, J. Blade, J.J. Lahuerta, M. Cavo, P. Tacchetti, E. Zamagni, M. Attal, H.M. Lokhorst, A. Desai, A. Cakana, K. Liu, H. van de Velde, D-L. Esseltine, P. Moreau

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	3279-3287
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	31
Issue number	26
Publication status	Published - 2013

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/23897961

Cite this

Sonneveld, P., Goldschmidt, H., Rosinol, L., Blade, J., Lahuerta, J. J., Cavo, M., Tacchetti, P., Zamagni, E., Attal, M., Lokhorst, H. M., Desai, A., Cakana, A., Liu, K., van de Velde, H., Esseltine, D.-L., & Moreau, P. (2013). Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. Journal of Clinical Oncology, 31(26), 3279-3287. http://www.ncbi.nlm.nih.gov/pubmed/23897961

@article{c13da10138334489a5b1bb8b8c83a280,

title = "Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.",

author = "P. Sonneveld and H. Goldschmidt and L. Rosinol and J. Blade and J.J. Lahuerta and M. Cavo and P. Tacchetti and E. Zamagni and M. Attal and H.M. Lokhorst and A. Desai and A. Cakana and K. Liu and {van de Velde}, H. and D-L. Esseltine and P. Moreau",

year = "2013",

language = "English",

volume = "31",

pages = "3279--3287",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "26",

}

Sonneveld, P, Goldschmidt, H, Rosinol, L, Blade, J, Lahuerta, JJ, Cavo, M, Tacchetti, P, Zamagni, E, Attal, M, Lokhorst, HM, Desai, A, Cakana, A, Liu, K, van de Velde, H, Esseltine, D-L & Moreau, P 2013, 'Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.', Journal of Clinical Oncology, vol. 31, no. 26, pp. 3279-3287. <http://www.ncbi.nlm.nih.gov/pubmed/23897961>

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. / Sonneveld, P.; Goldschmidt, H.; Rosinol, L. et al.
In: Journal of Clinical Oncology, Vol. 31, No. 26, 2013, p. 3279-3287.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

AU - Sonneveld, P.

AU - Goldschmidt, H.

AU - Rosinol, L.

AU - Blade, J.

AU - Lahuerta, J.J.

AU - Cavo, M.

AU - Tacchetti, P.

AU - Zamagni, E.

AU - Attal, M.

AU - Lokhorst, H.M.

AU - Desai, A.

AU - Cakana, A.

AU - Liu, K.

AU - van de Velde, H.

AU - Esseltine, D-L.

AU - Moreau, P.

PY - 2013

Y1 - 2013

M3 - Article

SN - 0732-183X

VL - 31

SP - 3279

EP - 3287

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 26

ER -